Clinical Trials Logo

Retinal Edema clinical trials

View clinical trials related to Retinal Edema.

Filter by:
  • None
  • Page 1

NCT ID: NCT05130385 Recruiting - Glaucoma Clinical Trials

High Resolution Optical Coherence Tomography

Start date: November 30, 2021
Phase:
Study type: Observational

Comparison of high-resolution optical coherence tomography (High-Res-OCT) to conventional imaging modalities for the diagnosis of eye diseases

NCT ID: NCT04690608 Not yet recruiting - Retinal Edema Clinical Trials

Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy

Resistant
Start date: December 1, 2024
Phase: Early Phase 1
Study type: Interventional

Prospective interventional study on 60 eyes of resistant diabetic macular edema and central retinal vein occlusion that will receive suprachoroidal injection of Triamcinolone Acetonide (SCTA).

NCT ID: NCT04501367 Recruiting - Vitrectomy Clinical Trials

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

Start date: April 27, 2021
Phase: Phase 4
Study type: Interventional

Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts following 27 gauge vitrectomy with internal limiting membrane peel

NCT ID: NCT01847638 Completed - Inflammation Clinical Trials

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery

QD
Start date: April 1, 2013
Phase: N/A
Study type: Interventional

To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.

NCT ID: NCT01273727 Completed - Macular Edema Clinical Trials

Ozurdex for Macular Edema Post Membrane Peeling

Start date: June 2010
Phase: Phase 2/Phase 3
Study type: Interventional

An epiretinal membrane is scar tissue on the retina that can cause blurring and distortion of vision and lead to swelling, or macular edema. Despite surgery to remove the scar tissue(membrane peeling), residual swelling of the retina may continue to interfere with vision. In this study the investigators will inject an implantable steroid device into the back, fluid-filled portion of the eye. Steroids have been found to decrease the swelling in the retina. Ozurdex™ is an implantable steroid. Once implanted, Ozurdex™ is slowly dissolved by the vitreous gel that fills the eye, releasing the steroid. The steroid drug delivery system in this study, known as Ozurdex™ has been FDA-approved by the US Food and Drug Administration (FDA) for decreasing swelling due to another condition in the eye. This study will help to find out whether or not this device Ozurdex™ is also effective for reducing the swelling of the retina in patients who have already had surgery to remove scar tissue on the retina.